Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (23296)	3/23/2007 10:10:22 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

My own view on this is that the POZN drug is very likely to be approved (I'm long POZN from much lower levels). The ALXA drug is much less certain - prochlorperazine can cause tardive dyskinesia, and we already have an example of the FDA migraine folks blanching at POZN's previous metoclopramide candidate for that very same reason. Also prochlorperazine is a known treatment for nausea in migraine, but I have my doubts that it will be effective as a monotherapy. So I have both safety and efficacy concerns here. Peter